Related Experiment Video

Updated: Aug 20, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

Pharmacogenomics of lipid-lowering agents: the impact on efficacy and safety

Aymen Shatnawi1, Zourayz Kamran2, Qusai Al-Share3

  • 1Department of Drug Discovery & Biomedical Sciences, College of Pharmacy, Medical University of South Carolina, 70 President St., Room 402, Charleston, SC 29425, USA.

Personalized Medicine
|November 23, 2022
PubMed

Insights

Genetic variations impact how well lipid-lowering drugs work and their side effects. Understanding pharmacogenomics can personalize treatment for better cardiovascular disease prevention and adherence.

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Drug Metabolism

Background:

  • Hyperlipidemia is a major risk factor for cardiovascular disease (CVD).
  • Lipid-lowering drugs are crucial for preventing atherosclerotic CVD but often have limited efficacy and adverse effects, causing discontinuation.
  • Gene polymorphisms are known to influence drug pharmacokinetics and toxicity.

Purpose of the Study:

  • To investigate the pharmacogenomics of lipid-lowering drugs.
  • To determine the impact of genetic variants on the efficacy and toxicity of these medications.

Main Methods:

  • Review of existing literature on gene polymorphisms and lipid-lowering drug response.
  • Analysis of key genes involved in drug metabolism and transport.
  • Correlation of genetic variants with clinical outcomes (efficacy and adverse events).

Main Results:

  • Specific genetic variants significantly affect the pharmacokinetic profiles of lipid-lowering agents.
  • Polymorphisms in key genes are associated with variable drug efficacy and risk of adverse reactions.
  • Pharmacogenomic data can predict individual responses to lipid-lowering therapies.

Conclusions:

  • Genetically guided lipid-lowering therapy improves treatment safety and patient adherence.
  • Personalized pharmacogenomic approaches enhance the long-term effectiveness of cardiovascular disease prevention.
  • Understanding genetic influences is key to optimizing lipid-lowering drug therapy.
Keywords:
PCSK9ezetimibefibrateshyperlipidemiastatinsvariants

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.1K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.5K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
752
Factors Affecting Drug Biotransformation: Biological01:19

Factors Affecting Drug Biotransformation: Biological

Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
207
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.1K
Nonlinear Pharmacokinetics: Role of Transporters01:27

Nonlinear Pharmacokinetics: Role of Transporters

A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
81
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs01:21

Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs

A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in...
323
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
70